MammOnc-DB, an integrative breast cancer data analysis platform for target discovery.

IF 7.6 2区 医学 Q1 ONCOLOGY
Santhosh Kumar Karthikeyan, Darshan S Chandrashekar, Snigdha Sahai, Sadeep Shrestha, Ritu Aneja, Rajesh Singh, Celina G Kleer, Sidharth Kumar, Zhaohui S Qin, Harikrishna Nakshatri, Upender Manne, Chad J Creighton, Sooryanarayana Varambally
{"title":"MammOnc-DB, an integrative breast cancer data analysis platform for target discovery.","authors":"Santhosh Kumar Karthikeyan, Darshan S Chandrashekar, Snigdha Sahai, Sadeep Shrestha, Ritu Aneja, Rajesh Singh, Celina G Kleer, Sidharth Kumar, Zhaohui S Qin, Harikrishna Nakshatri, Upender Manne, Chad J Creighton, Sooryanarayana Varambally","doi":"10.1038/s41523-025-00750-x","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer (BCa), a leading malignancy among women, is characterized by morphological and molecular heterogeneity. While early-stage, hormone receptor, and HER2-positive BCa are treatable, triple-negative BCa and metastatic BCa remains largely untreatable. Advances in sequencing and proteomic technologies have improved our understanding of the molecular alterations that occur during BCa initiation and progression and enabled identification of subclass-specific biomarkers and therapeutic targets. Despite the availability of abundant omics data in public repositories, user-friendly tools for multi-omics data analysis and integration are scarce. To address this, we developed a comprehensive BCa data analysis platform called MammOnc-DB ( http://resource.path.uab.edu/MammOnc-Home.html ), comprising data from more than 20,000 BCa samples. MammOnc-DB facilitates hypothesis generation and testing, biomarker discovery, and therapeutic targets identification. The platform also includes pre- and post-treatment data, which can help users identify treatment resistance markers and support combination therapy strategies, offering researchers and clinicians a comprehensive tool for BCa data analysis and visualization.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"35"},"PeriodicalIF":7.6000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008238/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00750-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Breast cancer (BCa), a leading malignancy among women, is characterized by morphological and molecular heterogeneity. While early-stage, hormone receptor, and HER2-positive BCa are treatable, triple-negative BCa and metastatic BCa remains largely untreatable. Advances in sequencing and proteomic technologies have improved our understanding of the molecular alterations that occur during BCa initiation and progression and enabled identification of subclass-specific biomarkers and therapeutic targets. Despite the availability of abundant omics data in public repositories, user-friendly tools for multi-omics data analysis and integration are scarce. To address this, we developed a comprehensive BCa data analysis platform called MammOnc-DB ( http://resource.path.uab.edu/MammOnc-Home.html ), comprising data from more than 20,000 BCa samples. MammOnc-DB facilitates hypothesis generation and testing, biomarker discovery, and therapeutic targets identification. The platform also includes pre- and post-treatment data, which can help users identify treatment resistance markers and support combination therapy strategies, offering researchers and clinicians a comprehensive tool for BCa data analysis and visualization.

MammOnc-DB,一个用于靶点发现的乳腺癌综合数据分析平台。
乳腺癌(BCa)是女性的主要恶性肿瘤,其特征是形态和分子的异质性。虽然早期、激素受体和her2阳性BCa是可以治疗的,但三阴性BCa和转移性BCa在很大程度上仍然无法治疗。测序和蛋白质组学技术的进步提高了我们对BCa起始和进展过程中发生的分子改变的理解,并使鉴定亚类特异性生物标志物和治疗靶点成为可能。尽管在公共存储库中有丰富的组学数据,但用于多组学数据分析和集成的用户友好工具却很少。为了解决这个问题,我们开发了一个全面的BCa数据分析平台,称为MammOnc-DB (http://resource.path.uab.edu/MammOnc-Home.html),其中包括来自20,000多个BCa样本的数据。MammOnc-DB促进假设生成和测试,生物标志物发现和治疗靶点鉴定。该平台还包括治疗前和治疗后的数据,可以帮助用户识别治疗耐药标记并支持联合治疗策略,为研究人员和临床医生提供BCa数据分析和可视化的综合工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
NPJ Breast Cancer
NPJ Breast Cancer Medicine-Pharmacology (medical)
CiteScore
10.10
自引率
1.70%
发文量
122
审稿时长
9 weeks
期刊介绍: npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信